Navigation Links
China Pharma Holdings, Inc. Reports Third Quarter 2008 Financial Results and Corporate Updates
Date:11/7/2008

y the SFDA in January 2008 for the treatment of edema caused by heart disease and hypertension. The Company continues to focus on expanding its capacity and distribution networks to support the development, manufacturing and sales of additional products.

Operating expenses in the third quarter of 2008 totaled $1.42 million, up 87.89% from approximately $0.76 million in the comparable period of 2007. The main reason was $0.46 million in Allowance for Bad Debt for this period, because in the same period last year, a substantial amount of aged receivables was collected, making that period's Allowance for Bad Debt, negative $0.17 million. Operating income in the third quarter of 2008 was approximately $4.7 million, an increase of 50.29% from approximately $3.1 million in the same period of 2007, while operating margin was approximately 37.23%, compared to 37.66% in the third quarter of 2007.

Gross profit in the third quarter of 2008 was approximately $6.12 million, up 57.62% compared to approximately $3.88 million in the third quarter of 2007. Gross margin was approximately 48.5%, higher than 46.79% in the prior year's period, and above the pharmaceutical industry's average of 34.2%.

Net income for the third quarter of 2008 rose 37.82% to approximately $4.25 million, or $0.10 per basic and diluted share, compared to $3.08 million, or $0.08 per basic and diluted share, in the same period a year ago. Diluted share count in the third quarter of 2008 was approximately 42.3 million, compared to approximately 37.2 million in the third quarter of 2007.

President and CEO, Ms. Zhilin Li, commented, "We are confident that our continued strong revenue growth for the third quarter of 2008 is a reflection of our focus on the largest segments of China's pharmaceutical market, in disease areas of high incidence and high mortality. Our rapid growth is supported by the ongoing delivery of new products, product technology, and branding. We are competitive with
'/>"/>

SOURCE China Pharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. China Pharma Holdings, Inc. to Host Third Quarter 2008 Earnings Conference Call at 10 a.m. EST Friday November 7, 2008
2. TomoTherapy Completes Acquisition of Linear Accelerator Manufacturer in China
3. China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26
4. China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter 2009 Financial Results
5. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
6. China Pharma Holdings, Inc. to Initiate Clinical Trials For New Antibiotic Combination
7. China Medical Technologies to Attend Credit Suisse Asian Healthcare Conference
8. China Sky One Medical, Inc. Acquires Drug to Treat Breast Lesions
9. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
10. China Sky One Medical, Inc. Receives Tax Refund
11. Mindray Medical to Exhibit New Products at 60th China International Medical Equipment Fair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... May 18, 2013 The “World Healthcare ... and studies the major market drivers, restraints, and opportunities ... world. , Browse , 89 ... in-depth TOC on "Healthcare IT Market" , ... customization on reports. , The global healthcare IT market ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 During Better ... loss should consider the legal protections they have, including ... problems arise with their child’s treatment or hearing aid ... Since 1927, the American Speech-Language-Hearing Association has used the ... and to promote treatment, such as cochlear implants, which ...
(Date:5/18/2013)... 2013 Adolescents, especially young males, who ... or “K2” are landing in emergency rooms across America. ... drug epidemic with a new treatment program for ... to research from the National Institute on Drug Abuse, ... among American teenagers. In 2012, 11 percent of high ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The ... Gov. John A. Kitzhaber, M.D., (D) to sign a ... by prohibiting minors under the age of 18 from ... become the third state in the nation to enact ... enacted similar indoor tanning bans for minors. Nationwide, 34 ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The topics that ... are scrum framework, scrum roles, scrum meetings, scrum artifacts, and ... (8 PDUs) for attending them. , These trainings are suitable ... is also ideal for those who will be a part ... those who want to explore Agile and Scrum, but are ...
Breaking Medicine News(10 mins):Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 3
... six major factors that affect how happy a woman ... been uncovered. Researchers writing in the open access journal ... well as final breast appearance, there are five other ... from Memorial Sloan-Kettering Cancer Center, New York, led a ...
... for Procrit, Aranesp, experts say, , , THURSDAY, April 30 ... that drugs such as Procrit and Aranesp, often used ... the risk of death and serious adverse events such ... (ESAs), have also been associated in prior studies with ...
... HOUSTON, April 30 As an expectant mother, her first official ... delivery arrives. Here are four unique ideas to make this ... women prescribed bed rest, this can be a vexing time. ... babies) to stay off her feet, but she is still very ...
... , April 30 ... biopharmaceutical company focused on in-licensing, developing and commercializing proprietary ... today announced that it will release its first quarter ... closes on Thursday, May 7, 2009. Cadence management will ...
... to treat Type 2 diabetes may have unintended effects on the ... some patients and a greater risk of pancreatic cancer in long-term ... In a study published in the online edition of the journal ... Center at UCLA found that sitagliptin, sold in pill form as ...
... Thoratec Corporation (Nasdaq: THOR ), a ... save, support and restore failing hearts, today announced that ... quarter of fiscal 2009 on Thursday, May 7.The company ... results and operating activities open to all interested parties ...
Cached Medicine News:Health News:What influences women's opinions on their breast surgery? 2Health News:Anemia Drugs May Raise Death Risk in Cancer Patients 2Health News:Anemia Drugs May Raise Death Risk in Cancer Patients 3Health News:Anemia Drugs May Raise Death Risk in Cancer Patients 4Health News:Four Unique Gifts for Expectant Moms Includes New Technology That Enhances Pre-Natal Bonding 2Health News:Popular diabetes treatment could trigger pancreatitis, pancreatic cancer 2Health News:Popular diabetes treatment could trigger pancreatitis, pancreatic cancer 3Health News:Thoratec Schedules First Quarter Conference Call, Webcast 2
(Date:5/17/2013)... May 17, 2013  Boehringer Ingelheim will contribute ... at the American Thoracic Society International Conference (ATS ... May 17 – 22. Data will ... the treatment of chronic obstructive pulmonary disease (COPD) ... as investigational compounds for asthma, idiopathic pulmonary fibrosis ...
(Date:5/17/2013)... , May 17, 2013 ... developer of oral drug delivery systems, announced today that ... cleared the Company,s Investigational New Drug application(IND) for ORMD-0801, ... pleased to have the FDA clearance to proceed," stated ... "The upcoming trial is a major milestone for Oramed ...
(Date:5/16/2013)... NORTH CHICAGO, Ill. and MECHELEN, ... NV (Euronext: GLPG) and AbbVie (NYSE: ABBV ... development collaboration to include Crohn,s disease.  Galapagos will fund ... which is designed to facilitate rapid progression into Phase ... Q2 2015, AbbVie will pay Galapagos $50 million.  The ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... March 16 Healthpoint today announced that it has ... of HP802-247 in venous leg ulcers. HP802-247 is a ... is designed to determine the effectiveness of two cell ... with standard care, compared to placebo plus standard care, ...
... Aims To Enhance Precision and Reduce High Failure ... Hamilton, N.J., March 16 ICON (Nasdaq: ... outsourced development services to the pharmaceutical, biotechnology and ... in centralized psychiatric patient evaluation, today announced that ...
Cached Medicine Technology:Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 2Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 3ICON and MedAvante Sign Alliance Agreement 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,409-7) or contact custom...
... samples of moderate viscosity and density. Proven ergonomic design reduces hand fatigue, ... Volume Range (ul) ... 1.0~1.5 Imprecision(%) ... 10 ...
... is a fully adjustable, air-displacement pipette with ... the latest member of the Pipetman family, ... accuracy, and precision. We also added a ... our customers. Eight models cover the full ...
... Finnpipette Digital offers improved ergonomics for ... handle, modified grippy finger rest and ... comfort and efficiency. Finnpipette Digitals also ... gearing mechanism (pat. pend.) and super ...
Medicine Products: